GlassScriptPhysician profile
Soubrata V Raikar
NPI 1154495125
$37,516.44
in general payments reported to CMS, 2019-2025
37 companies · $6,748 in 2025
The $6,748 reported for 2025 was more than what 93% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,770 · 2020: $606 · 2021: $5,064 · 2022: $9,349 · 2023: $1,086 · 2024: $9,894 · 2025: $6,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,780 · Food and Beverage: $4,283 · Travel and Lodging: $4,170 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,780.00 |
| Food and Beverage | $4,282.77 |
| Travel and Lodging | $4,169.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $495.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinefrontier, INC. | $19,642.60 | 2019-2025 | Sijfuse, Nanofuse, Inspan |
| Biotronik Nro, INC. | $7,260.73 | 2023-2025 | Prospera, Biotronik |
| Flowonix Medical Incorporated | $5,179.74 | 2019-2022 | |
| Medtronic, INC. | $1,273.78 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Na |
| Forte Bio-Pharma LLC | $950.42 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Boston Scientific Corporation | $828.26 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Vertiflex, INC. | $322.62 | 2019 | |
| Nevro Corp. | $299.86 | 2019-2022 | |
| Stimwave Technologies Incorporated | $258.73 | 2019 | |
| Zavation Medical Products, LLC | $233.09 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $148.94 | 2022-2024 | Xtampza, Belbuca |
| Si-Bone, INC. | $119.35 | 2022-2025 | |
| Nalu Medical, INC. | $100.32 | 2021-2025 | Nalu Neurostimulation System |
| Abbvie INC. | $78.82 | 2021-2024 | |
| Pfizer INC. | $75.81 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $71.81 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $55.95 | 2019 | |
| Xtant Medical INC | $54.28 | 2023 | |
| Protega Pharmaceutials INC | $52.31 | 2025 | Roxybond |
| Abbott Laboratories | $51.13 | 2020-2021 | |
| Lundbeck LLC | $47.68 | 2022-2024 | Vyepti |
| Spr Therapeutics, INC | $45.46 | 2022-2023 | Sprint Pns System |
| Kowa Pharmaceuticals America, INC. | $44.49 | 2022-2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $39.83 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $34.54 | 2022 | |
| Mercury Enterprises, INC. | $30.81 | 2022 | |
| Grt US Holding, INC. | $30.79 | 2021-2022 | |
| Lilly USA, LLC | $30.74 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.97 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.66 | 2021 | |
| Bioventus LLC | $15.40 | 2019 | |
| Vertos Medical, INC. | $15.14 | 2023 | Mild Device Kit |
| Shionogi INC | $15.01 | 2019 | |
| Csl Behring | $13.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.23 | 2019 | |
| Biodelivery Sciences International, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soubrata Raikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.